Articles From: Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase to Galena Biopharma Launches Abstral(R) (fentanyl) Sublingual Tablets for the Treatment of Breakthrough Cancer Pain


2014/1/23
NORCROSS, Ga., Jan.
Sign-up for Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase investment picks
NORCROSS, Ga., Sept.
Sign-up for Galectin Therapeutics Leadership to Present at Three Upcoming Conferences investment picks
2014/2/24
NORCROSS, Ga., Feb.
Sign-up for Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop investment picks
2014/1/6
NORCROSS, Ga., Jan.
Sign-up for Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis investment picks
2014/3/21
NORCROSS, Ga., March 21, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the year ended December 31, 2013.
Sign-up for Galectin Therapeutics Reports 2013 Financial Results investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Reports Second Quarter 2013 Financial Results investment picks
2014/2/26
NORCROSS, Ga., Feb.
Sign-up for Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease investment picks
2014/3/25
NORCROSS, Ga., March 25, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that on Monday, March 31, 2014, the Company will report results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease (NASH) with advanced fibrosis.
Sign-up for Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease investment picks
2014/2/5
NORCROSS, Ga., Feb.
Sign-up for Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference investment picks
2014/1/13
Acquisition adds GALE-401 (Anagrelide CR) to expand Galena's product pipeline.
Sign-up for Galena Biopharma Acquires Mills Pharmaceuticals, LLC investment picks
2014/1/14
Galena licenses commercial rights to Dr.
Sign-up for Galena Biopharma and Dr. Reddy's Announce Strategic Partnership for NeuVax(TM) in India investment picks
PORTLAND, Ore., Sept.
Sign-up for Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants investment picks
Folate Binding Protein (FBP) shown to be safe and immunogenic in its Phase 1 trial Phase 2a trial expected to initiate by year end PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Announces Initial Results From the Folate Binding Protein Vaccine Phase 1 Trial at the Society for Immunotherapy of Cancer Conference investment picks
NeuVax induces a full immune response in treated patients and creates an immune memory to target residual cancer cells Phase 3 PRESENT HER2 1+/2+ patients confirmed as optimal treatment population PORTLAND, Ore., Oct.
Sign-up for Galena Biopharma Announces Oral Presentation at the American College of Surgeons Clinical Congress 2013 investment picks
2013/9/13
PORTLAND, Ore., Sept.
Sign-up for Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants investment picks
2013/9/12
PORTLAND, Ore., Sept.
Sign-up for Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants investment picks
2014/2/28
PORTLAND, Ore., Feb.
Sign-up for Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual Property With Patent Acceptance in Australia investment picks
PORTLAND, Ore., Aug.
Sign-up for Galena Biopharma Expands NeuVax(TM) Intellectual Property With European Allowance investment picks
2013/9/3
RELIEF:  R apid E valuation of L ifestyle, I ndependence, and E limination of breakthrough cancer pain with F reedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets Galena debuts Abstral campaign at PAINWeek September 4-7, 2013 in Las Vegas Galena to generate sales revenue in 2013 with significant progress towards Abstral® commercial launch in the fourth quarter.
Sign-up for Galena Biopharma Initiates RELIEF Patient Registry for Abstral(R) (fentanyl) Sublingual Tablets investment picks
2014/2/14
PORTLAND, Ore., Feb.
Sign-up for Galena Biopharma Issues Letter to Shareholders investment picks
2013/10/3
PORTLAND, Ore., Oct.
Sign-up for Galena Biopharma Launches Abstral(R) (fentanyl) Sublingual Tablets for the Treatment of Breakthrough Cancer Pain investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase to Galena Biopharma Launches Abstral(R) (fentanyl) Sublingual Tablets for the Treatment of Breakthrough Cancer Pain
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity